|Other Names||Keratin, type I cytoskeletal 9, Cytokeratin-9, CK-9, Keratin-9, K9, KRT9|
|Target/Specificity||The synthetic peptide sequence used to generate the antibody AP7312c was selected from the Center region of human KRT9. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.|
|Format||Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||May serve an important special function either in the mature palmar and plantar skin tissue or in the morphogenetic program of the formation of these tissues. Plays a role in keratin filament assembly.|
|Tissue Location||Expressed in the terminally differentiated epidermis of palms and soles.|
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
KRT9 is the type I keratin 9, an intermediate filament chain expressed only in the terminally differentiated epidermis of palms and soles. Mutations in this protein cause epidermolytic palmoplantar keratoderma.
Feng,W., Han,W. Eur J Dermatol 18 (4), 387-390 (2008)Zhao,J.J., Zhang,Z.H. Int. J. Dermatol. 47 (6), 634-637 (2008)Torchard,D., Blanchet-Bardon,C. Nat. Genet. 6 (1), 106-110 (1994)Reis,A., Kuster,W. Hum. Genet. 90 (1-2), 113-116 (1992)
If you have any additional inquiries please email technical services at email@example.com.